Case Series
A Case Series of Persistent SARS-CoV-2 Infection in Immunocompromised Pediatric Patients
| Cases | Age | Cause of immunosuppression | Duration of persistent symptoms (from initial diagnosis with COVID-19 until admission with acute respiratory failure) | Associated complications | Management | Clinical outcome |
| Case 1 | 16-year-old | H/o ALL s/p peripheral stem cell transplantation | 3-4 weeks | Diffuse alveolar hemorrhage Atypical hemolytic-uremic syndrome Pulmonary infarction secondary to invasive mucormycosis | Hydrocortisone Eculizumab Vancomycin Cefepime Amphotericin (after pulmonary infarction) | Death |
| Case 2 | 12-year-old | H/o ALL s/p bone marrow transplant | 4 weeks | Diffuse alveolar hemorrhage Pulmonary embolism | Remdesivir Hydrocortisone Tocilizumab Vancomycin Cefepime Amphotericin | Discharge home on room air |
| Case 3 | 14-year-old | P-ANCA vasculitis with end-stage renal disease | 5 weeks | Diffuse alveolar hemorrhage Pneumothorax Pneumomediastinum Hyperferritinemia | Remdesivir Hydrocortisone Anakinra IVIG Plasmapheresis Vancomycin Cefepime Amphotericin | Discharge home on room air |
| Case 4 | 19-year-old | Granulomatosis with polyangiitis | 5 weeks | Diffuse alveolar hemorrhage | Remdesivir Hydrocortisone Unasyn | Discharge home on room air |
|
|